argenx
argenx's revenue rose 88.6% to $4.2 billion in fiscal 2025. Its operating margin was 24.8%, up from −1.0% a year earlier. Free cash flow was $679 million. The diluted share count rose 1.3%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What argenx does
argenx is a biotechnology company, based in the Netherlands with research in Belgium, that makes antibody medicines for autoimmune diseases, in which the body's immune system attacks its own tissue. Its one approved medicine, VYVGART, treats generalized myasthenia gravis (gMG), a disease that causes muscle weakness, and chronic inflammatory demyelinating polyneuropathy (CIDP), a nerve disorder, plus immune thrombocytopenia (ITP), a blood disorder, in Japan. It comes as a drip into a vein or as an injection under the skin, including a prefilled syringe, and is approved in more than 30 countries.
Nearly all of its money comes from selling VYVGART through its own sales teams in the U.S., Europe, Japan and Canada, and through a partner, Zai Lab, in Greater China. In 2025 it reported product net sales of $4.2 billion, and VYVGART passed $1 billion in sales in a single quarter for the first time. The company says VYVGART reached more than 19,000 patients. It names AstraZeneca, AbbVie, Amgen, Johnson & Johnson and Novartis among its competitors in autoimmune disease.
argenx is testing VYVGART's active ingredient, efgartigimod, in more than ten other diseases, along with newer drugs such as empasiprubart and adimanebart. Contract makers, chiefly Lonza and Fujifilm, produce its medicines. It had 1,863 full-time employees at the end of 2025.
Its biggest risks, as it describes them
- Its sales rest almost entirely on one medicine, VYVGART, so anything that hurts it would hurt the whole business.
- Competing drugs for the same diseases, including cheaper copies (biosimilars) once its exclusivity runs out.
- Drug price controls, such as Medicare price negotiation in the U.S., that could cut what it can charge.
- Clinical trials of new uses and new drugs may fail or be delayed, or regulators may not approve them.
- Its reliance on a few contract manufacturers, chiefly Lonza and Fujifilm, to make its medicines.
Income statement
From fiscal 2024 to 2025, earnings per share grew 53.1% a year and net income 55.1% a year, as new shares raised the share count by 1% and diluted each share's earnings.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,335 | 801 | 2,049 | 1,500 | 3,491 |
| Debt incl. finance leases | — | — | 7 | — | — |
| Net debt (negative means net cash) | — | — | −2,042 | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | 0.0x | — | — |
| Interest coverage | −76.2x | −184.4x | −469.1x | −8.8x | 258.2x |
| Current ratio | 8.4x | 9.2x | 9.8x | 7.3x | 5.2x |
| Quick ratio | 8.1x | 8.4x | 9.0x | 6.7x | 4.9x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −930.8% | 6,234.1% | 104.6% |
| Altman Z'' | 12.66 | 11.80 | 10.58 |
| Accruals ratio | 3.3% | 17.1% | 8.2% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | Fail | Pass | Fail |
| Revenue rose relative to assets | Pass | Pass | Pass |
| F-score | — | — | — |
Compare
Put argenx side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| argenx | FY25 | 88.6% | 24.8% | 16.0% | — | — | — | |
| Incyte | FY25 | 21.2% | 29.5% | 26.4% | 79.4% | −2.2x | 8 | Compare |
| BioMarin Pharmaceutical | FY25 | 12.9% | 12.7% | 22.5% | 5.8% | −2.0x | 5 | Compare |
| United Therapeutics | FY25 | 10.6% | 46.9% | 32.7% | — | — | — | Compare |
| BioNTech | FY25 | 4.3% | −49.0% | 9.8% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | — | — | 22 | 78 | 41 | 497 | 10 | 36 | 2,252 | 4,248 |
| Revenue growth | — | — | — | 265.2% | −47.4% | 1,105.7% | −98.0% | 254.4% | 6,237.9% | 88.6% |
| Gross profit | — | — | — | — | — | — | −19 | −82 | 2,025 | 3,797 |
| Research and development | — | — | 84 | 221 | 371 | 580 | 663 | 860 | 983 | 1,364 |
| Operating income | — | — | −82 | −199 | −478 | −349 | −720 | −425 | −22 | 1,054 |
| Net income | — | — | −67 | −181 | −608 | −408 | −710 | −295 | 833 | 1,292 |
| Diluted EPS (US$) | — | — | — | −4.69 | −13.40 | −7.99 | −13.05 | −5.16 | 12.78 | 19.57 |
| Diluted shares (millions) | 19 | 25 | 33 | 39 | 45 | 51 | 54 | 57 | 65 | 66 |
| Cash flow | ||||||||||
| Cash from operations | — | — | — | 152 | −398 | −607 | −863 | −420 | −83 | 685 |
| Capital expenditure | — | — | — | 2 | 1 | 4 | 1 | 1 | 2 | 6 |
| Free cash flow | — | — | — | 150 | −400 | −610 | −864 | −421 | −85 | 679 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | — | — | — | 44 | 97 | 179 | 157 | 233 | 235 | 248 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | — | — | 322 | 372 | 1,217 | 1,335 | 801 | 2,049 | 1,500 | 3,491 |
| Debt incl. finance leases | — | — | — | — | — | — | — | 7 | — | — |
| Total assets | — | — | — | 1,610 | 2,279 | 2,850 | 3,134 | 4,542 | 6,202 | 8,683 |
| Total liabilities | — | — | — | 430 | 605 | 316 | 321 | 445 | 704 | 1,360 |
| Shareholders' equity | — | — | 616 | 1,180 | 1,674 | 2,534 | 2,814 | 4,098 | 5,498 | 7,323 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | −193.6% | −231.6% | 89.9% | 89.4% |
| Operating margin | — | — | −381.0% | −253.5% | −1,158.1% | −70.1% | −7,184.7% | −1,196.2% | −1.0% | 24.8% |
| Net margin | — | — | −310.2% | −230.9% | −1,475.3% | −82.1% | −7,077.5% | −830.4% | 37.0% | 30.4% |
| Free cash flow margin | — | — | — | 191.0% | −968.7% | −122.8% | −8,614.0% | −1,185.2% | −3.8% | 16.0% |
| Rule of 40 (growth + FCF margin) | — | — | — | 456.2% | −1,016.2% | 983.0% | −8,712.0% | −930.8% | 6,234.1% | 104.6% |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | — | — | — | −42.6% | −19.4% | −26.5% | −8.5% | 17.4% | 20.1% |
| Return on assets | — | — | — | — | −31.3% | −15.9% | −23.7% | −7.7% | 15.5% | 17.4% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |